Clinical Relevance of Cyclic GMP Modulators: A Translational Success Story of Network Pharmacology

J. M. Oettrich; V. T. Dao; J. Frijhoff; P. W. M. Kleikers; Ana Casas Guijarro; A. J. Hobbs; H. H. H. W. Schmidt

doi:10.1002/cpt.336

Clinical Relevance of Cyclic GMP Modulators: A Translational Success Story of Network Pharmacology

J. M. Oettrich, V. T. Dao, J. Frijhoff, P. W. M. Kleikers, Ana Casas Guijarro, A. J. Hobbs, H. H. H. W. Schmidt^*

^*Corresponding author for this work

Pharmacology and Personalised Medicine

Research output: Contribution to journal › Article › Academic › peer-review

64 Downloads (Pure)

Abstract

Therapies that modulate cyclic guanosine-30-50-monophosphate (cGMP) have emerged as one of the most successful areas in recent drug discovery and clinical pharmacology. Historically, their focus has been on cardiovascular disease phenotypes; however, cGMP's relevance is likely to go beyond this rather limited organ-based set of indications. Moreover, the multitude of targets and their apparent interchangeability is a proof-of-concept of network pharmacology.

Original language	English
Pages (from-to)	360-362
Journal	Clinical Pharmacology & Therapeutics
Volume	99
Issue number	4
DOIs	https://doi.org/10.1002/cpt.336
Publication status	Published - Apr 2016

Access to Document

10.1002/cpt.336

Full TextFinal published version, 626 KBLicence: Taverne

Cite this

@article{501d09095e77427a944aa7b3cfae2d35,

title = "Clinical Relevance of Cyclic GMP Modulators: A Translational Success Story of Network Pharmacology",

abstract = "Therapies that modulate cyclic guanosine-30-50-monophosphate (cGMP) have emerged as one of the most successful areas in recent drug discovery and clinical pharmacology. Historically, their focus has been on cardiovascular disease phenotypes; however, cGMP's relevance is likely to go beyond this rather limited organ-based set of indications. Moreover, the multitude of targets and their apparent interchangeability is a proof-of-concept of network pharmacology.",

author = "Oettrich, {J. M.} and Dao, {V. T.} and J. Frijhoff and Kleikers, {P. W. M.} and {Casas Guijarro}, Ana and Hobbs, {A. J.} and Schmidt, {H. H. H. W.}",

year = "2016",

month = apr,

doi = "10.1002/cpt.336",

language = "English",

volume = "99",

pages = "360--362",

journal = "Clinical Pharmacology & Therapeutics",

issn = "0009-9236",

publisher = "Wiley",

number = "4",

}

TY - JOUR

T1 - Clinical Relevance of Cyclic GMP Modulators: A Translational Success Story of Network Pharmacology

AU - Oettrich, J. M.

AU - Dao, V. T.

AU - Frijhoff, J.

AU - Kleikers, P. W. M.

AU - Casas Guijarro, Ana

AU - Hobbs, A. J.

AU - Schmidt, H. H. H. W.

PY - 2016/4

Y1 - 2016/4

N2 - Therapies that modulate cyclic guanosine-30-50-monophosphate (cGMP) have emerged as one of the most successful areas in recent drug discovery and clinical pharmacology. Historically, their focus has been on cardiovascular disease phenotypes; however, cGMP's relevance is likely to go beyond this rather limited organ-based set of indications. Moreover, the multitude of targets and their apparent interchangeability is a proof-of-concept of network pharmacology.

AB - Therapies that modulate cyclic guanosine-30-50-monophosphate (cGMP) have emerged as one of the most successful areas in recent drug discovery and clinical pharmacology. Historically, their focus has been on cardiovascular disease phenotypes; however, cGMP's relevance is likely to go beyond this rather limited organ-based set of indications. Moreover, the multitude of targets and their apparent interchangeability is a proof-of-concept of network pharmacology.

U2 - 10.1002/cpt.336

DO - 10.1002/cpt.336

M3 - Article

SN - 0009-9236

VL - 99

SP - 360

EP - 362

JO - Clinical Pharmacology & Therapeutics

JF - Clinical Pharmacology & Therapeutics

IS - 4

ER -